Cet ouvrage fait partie de la bibliothèque YouScribe
Obtenez un accès à la bibliothèque pour le lire en ligne
En savoir plus

Frost & Sullivan: New Testing Options Bring Prenatal Testing Market to the Forefront in the U.S.

3 pages
Frost & Sullivan: New Testing Options Bring Prenatal Testing Market to the Forefront in the U.S. PR Newswire MOUNTAIN VIEW, California, June 5, 2012 - Prenatal testing services are an option for parents-to-be MOUNTAIN VIEW, California, June 5, 2012 /PRNewswire/ -- Prenatal testing is an available choice for pregnant women around the world to obtain information at their discretion about the fetus they are carrying. Women may choose to detect chromosome abnormalities in the fetus. For example, mothers-to-be are often told by their OBGYNs about the increased risk of chromosomal abnormality with advanced maternal age. In the United States, the trend of increasing maternal age for women may also increase the use of prenatal tests. Analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com) Strategic Analysis of the U.S. Prenatal Testing Market research finds that the market earned revenues of $1.28 billion in 2010 and estimates this to reach $1.59 billion in 2017. In this analysis, Frost & Sullivan's in vitro diagnostic (IVD) industry analysts thoroughly examine the following market segments: maternal serum screen, nuchal translucency (NT) ultrasound, karyotype, prenatal fluorescent in situ hybridization (FISH), and prenatal chromosomal array. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.
Voir plus Voir moins
Frost & Sullivan: New Testing Options Bring
Prenatal Testing Market to the Forefront in the
U.S.
PR Newswire
MOUNTAIN VIEW, California, June 5, 2012
- Prenatal testing services are an option for parents-to-be
MOUNTAIN VIEW, California
,
June 5, 2012
/PRNewswire/ -- Prenatal testing is an
available choice for pregnant women around the world to obtain information at
their discretion about the fetus they are carrying. Women may choose to
detect chromosome abnormalities in the fetus. For example, mothers-to-be
are often told by their OBGYNs about the increased risk of chromosomal
abnormality with advanced maternal age. In
the United States
, the trend of
increasing maternal age for women may also increase the use of prenatal
tests.
Analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com)
Strategic Analysis of the U.S. Prenatal Testing Market
research finds
that the market earned revenues of
$1.28 billion
in 2010 and estimates this to
reach
$1.59 billion
in 2017. In this analysis, Frost & Sullivan's in vitro diagnostic
(IVD) industry analysts thoroughly examine the following market segments:
maternal serum screen, nuchal translucency (NT) ultrasound, karyotype,
prenatal fluorescent in situ hybridization (FISH), and prenatal chromosomal
array.
If you are interested in more information on this research, please send an
email to Britni Myers, Corporate Communications, at britni.myers@frost.com,
with your full name, company name, title, telephone number, company email
address, company Web site, city, state and country.
"Prenatal diagnostic companies aim to develop tests that give women the
information they want about their pregnancy," said Frost & Sullivan Industry
Analyst Winny Tan. "Should pregnant women elect prenatal testing, these
companies understand that is critical for the test results to be as conclusive and
reliable as possible as this is a sensitive and very personal area."
Highly perceptive testing methods are available in prenatal testing. Prenatal
chromosomal array detects serious chromosomal abnormalities at a higher
resolution than traditional karyotyping. While prenatal microarray requires an
invasive procedure, non-invasive prenatal diagnostics (NIPD) on the other hand,
does not require an amniocentesis or chorionic villus sampling (CVS). Several
companies are focused on bringing NIPD to the market.
"This industry is witnessing major technological developments," said Tan.
"Cutting-edge techniques like comparative genomic hybridization (ArrayCGH)
microarray and sequence analysis of circulating fetal DNA found in maternal
blood are being applied to prenatal testing by companies. Included in Frost &
Sullivan research findings is that 60 to 70 percent of all pregnancies in
the
United States
receive a maternal serum screen. A much smaller group
undergoes diagnostic testing that is invasive."
This Frost & Sullivan research is an objective overview of the trends
and dynamics of an industry and its patients within
the United States
.